ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Xifeng Wu
Matched on ORCID iD 0000-0001-5174-3769; OpenAlex author ID A5066957198. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 38
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper
Papers 7
- Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins. Last author DOI 10.3389/fimmu.2023.1189161↗
- A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk. Co-author DOI 10.1016/j.xhgg.2021.100078↗
- "Sugar-Sweetened Beverages" Is an Independent Risk From Pancreatic Cancer: Based on Half a Million Asian Cohort Followed for 25 Years. Co-author DOI 10.3389/fonc.2022.835901↗
- Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.02.012↗
- Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejca.2017.12.023↗
- Identification of genetic variants predictive of early onset pancreatic cancer through a population science analysis of functional genomic datasets. First author DOI 10.18632/oncotarget.10924↗
- Susceptibility locus for lung cancer at 15q25.1 is not associated with risk of pancreatic cancer. First author DOI 10.1097/mpa.0b013e318219dafe↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xiawei Li · 1 shared paper, 2023 · strength 0.17
- Xin Dong · 1 shared paper, 2023 · strength 0.17
- Sai Pan · 1 shared paper, 2023 · strength 0.17
- Yulian Wu · 1 shared paper, 2023 · strength 0.17
- Huamin Wang · 2 shared papers, 2018–2022 · strength 0.17
- Paper A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic ca… DOI 10.1016/j.xhgg.2021.100078↗
- Paper Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.02.012↗
- Donghui Li · 2 shared papers, 2018–2022 · strength 0.17
- Paper A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic ca… DOI 10.1016/j.xhgg.2021.100078↗
- Paper Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.02.012↗
- Chi Pang Wen · 1 shared paper, 2022 · strength 0.16
- Ro‐Ting Lin · 1 shared paper, 2022 · strength 0.16
- Chien‐Hua Chen · 1 shared paper, 2022 · strength 0.16
- Chad Daniel Huff · 1 shared paper, 2022 · strength 0.12
- Paul A Scheet · 1 shared paper, 2022 · strength 0.12
- Yao Yu · 1 shared paper, 2022 · strength 0.12
- Lisa Cannon‐Albright · 1 shared paper, 2022 · strength 0.12
- Ping Chang · 1 shared paper, 2022 · strength 0.12
- Jennifer B. Permuth · 1 shared paper, 2022 · strength 0.12
- Subrata Sen · 2 shared papers, 2011–2016 · strength 0.09
- Jinyun Chen · 2 shared papers, 2011–2016 · strength 0.09
- Ann McNeill Killary · 2 shared papers, 2011–2016 · strength 0.09
- Marsha L. Frazier · 2 shared papers, 2011–2016 · strength 0.09
- David W. Chang · 1 shared paper, 2018 · strength 0.07
- Yang Deng · 1 shared paper, 2018 · strength 0.07
- Alison P. Klein · 1 shared paper, 2018 · strength 0.07
- Wei Chen · 1 shared paper, 2016 · strength 0.06
- Randall E. Brand · 1 shared paper, 2016 · strength 0.06
- Milind M. Javle · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.